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Brief Technique Reportsdystrophic nature, with no severe dilatation of the aortic
root.
The third question relates to the risk of complete atrioven-
tricular block after CoreValve System implantation. Several
predictors, including pre-existing right bundle branch block,
have been determined and should lead to careful and pro-
longed predischarge monitoring, all the more because these
conduction disturbances can be delayed, as was the case in
the present report.5
In the future, the treatment of AR by means of TAVI will
probably remain restricted to very particular and individual
cases but might be life-saving or contribute to an improve-
ment in the functional status of patients with no other
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New York, NYLeft ventricular assist devices (LVADs) are playing an in-
creasingly important role in the management of end-stage
heart failure, especially with the advances in technology in
implantable LVADs. Placement of an implantable LVAD
generally requires a median sternotomy, and this approach
might not be suitable for unstable patients with difficult
resternotomy. Even in such a situation, however, current
state-of-the-art technology can provide mechanical circula-
tory support either with extracorporeal membrane oxygena-
tion (ECMO) or, more recently, with percutaneous
LVADs.1,2 The shortcoming of the latter modalities is that
they are not designed for prolonged periods of support.
Here we describe a unique configuration of the CentriMag
LVAD (Thoratec Corp, Pleasanton, Calif) that allowed rapid
off-pump placement of the device without performing a ster-
notomy.CLINICAL SUMMARY
The patient was a 50-year-old man (height, 180 cm;
weight, 105 kg) with nonischemic dilated cardiomyopathy.
He previously had 2 sternotomies; the first was an aortic
valve replacement with a mechanical valve for congenital
bicuspid aortic valve 8 years ago, and the second was a hem-
iarch repair of a type A aortic dissection 4 years ago. The
patient first had symptoms of congestive heart failure
(CHF) about 6 years ago, with recent progression requiring
multiple hospitalizations, and was listed for heart transplan-
tation. His condition recently further deteriorated, with
acutely decompensated CHF and ventricular arrhythmia re-
quiring admission to the intensive care unit. Although CHF
improved with infusion of inotropic agents, ventricular
arrhythmia persisted and became more frequent, with
multiple firings of his implantable cardioverter defibrillator.
Intra-aortic balloon pump therapy was not applicable
because of the remaining aortic dissection in the descending
aorta. At this point, urgent LVAD support was deemed
necessary.
The patient was taken to the operating room. In the supine
position general anesthesia was induced with a single-lumen
endotracheal tube. The previous right axillary artery cannu-
lation site was opened, and the artery was exposed. A left an-
terior minithoracotomy through the sixth intercostal space
was performed, and the left ventricular apex was exposed
by dissecting some loose adhesion inside of the pericardium.ery c October 2010
FIGURE 1. An inflow cannula was inserted into the left ventricle through
the apex, which was exposed with an anterior left minithoracotomy.
Brief Technique ReportsHeparin (150 U/kg) was administered intravenously. An
8-mm graft was sewn end to side to the right axillary artery,
and a 24F EOPA arterial cannula (Medtronic, Inc, Minneap-
olis, Minn), brought through a separate skin incision, was in-
serted and secured to the graft. Next, 2–0 double purse-string
sutures buttressed by bovine pericardial pledgets were
placed at the apex, and the apex was punctured with a needle
through which a guidewire was inserted into the left ventri-
cle. After serial dilatation with the Vascular Dilator Kit
(Estech, Inc, San Ramon, Calif), a 40F Lighthouse malleable
cannula (Edwards Lifesciences LLC, Irvine, Calif) was in-
serted into the left ventricle, and the purse-string sutures
were snared. The position of the left ventricular cannula
was confirmed with transesophageal echocardiographic
analysis. The cannula was secured to the snares and was
brought out though a separate skin incision at the left ante-
rior chest (Figure 1). The cannulae were connected to the
CentriMag LVAD, and the LVAD was actuated with
caution to maintain forward flow through the mechanical
aortic valve. A flow of more than 4 L/min was achieved eas-
ily. No blood transfusion was required. The heparin drip was
resumed immediately for the mechanical aortic valve. The
patient was extubated on postoperative day 1 and is waiting
for heart transplantation in stable condition. No further ven-
tricular arrhythmia was observed.
DISCUSSION
Recently reported 30-day survival rates after long-term
mechanical circulatory support device insertion are approx-
imately 80% to 90%.3 Estimated operative mortality rates
from the revised Columbia screening scale, developed
with a focus on operative mortality, are approximately 5%
for low-risk patients and approximately 45% for high-risk
patients.4 An important lesson learned from the previous
experience was that patient selection is the key to the success
of LVAD implantation, and in fact, better patient selection
has contributed to decreasing operative mortality.5,6 In real-
ity, however, cardiac surgeons are frequently faced with
a critically ill patient who has a high-risk profile but likely
will not survive without ventricular assist device (VAD)
support. The outcome with an implantable LVAD in this sit-
uation has been shown to be unsatisfactory, and therefore al-
ternate measures are sought in these circumstances. These
include ECMO, a percutaneous VAD, and a short-term/
nonimplantable VAD, such as CentriMag or Abiomed
BVS/AB 5000. As stated above, ECMO and a percutaneous
VAD allow only limited duration of support, and the use of
a short-term VAD with the regular insertion technique re-
quires a median sternotomy. None of these devices or tech-
niques would have accommodated our patient with 2 prior
sternotomies and ideally requiring full postoperative mobili-
zation/rehabilitation before undergoing heart transplanta-
tion. Accordingly, we chose the left ventricular apex as
a cannulation site for the inflow cannula and the rightThe Journal of Thoracic and Caaxillary artery as that for the outflow cannula, thus avoiding
a third sternotomy. The right axillary artery was chosen over
the left because of the existing implantable cardioverter de-
fibrillator. The feasibility of these access sites has been
established through experience in the transapical approach
for aortic valve replacement and right axillary cannulation
for aortic surgery. This configuration allowed a less invasive
approach and yet provided excellent flow. For this particular
patient, forward flow through his mechanical aortic valve
was maintained to prevent thrombus formation by adjusting
the LVAD flow. Although the CentriMag is currently ap-
proved only for short-term support, in our program we
have used the CentriMag VAD short-term/nonimplantable
support out of clinical necessity for up to several months
with satisfactory outcomes. Therefore, we expect that
LVAD support with the current configuration can be contin-
ued for a relatively long time until the patient receives a heart
transplant.References
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